SynthesisDigestive diseases and sciences2012
Anti-Saccharomyces cerevisiae antibodies associate with phenotypes and higher risk for surgery in Crohn's disease: a meta-analysis.
Synthesis in Digestive diseases and sciences, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 1 synthesis or guideline pooled it, 66 citations in OpenAlex.
- Prognostic biomarkers to identify patients likely to develop severe Crohn's disease: a systematic review.Health technology assessment (Winchester, England) · 2021Pooled it
- Impact of celiac disease on the clinical course of inflammatory bowel disease: CEL_EII study by GETECCU.Therapeutic advances in gastroenterology · 2026Article
- Recent Trend of Laboratory Tests in Common Gastrointestinal Tract Disorders.Diagnostics (Basel, Switzerland) · 2025Review
- Role of fungus in inflammatory bowel disease: The butterfly effect?Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology · 2024Article
- Precision Medicine in Inflammatory Bowel Disease: A Spotlight on Emerging Molecular Biomarkers.Biomedicines · 2024Review
- Biomarkers in IBD: What to Utilize for the Diagnosis?Diagnostics (Basel, Switzerland) · 2023Review
- Genes and Microbiota Interaction in Monogenic Autoimmune Disorders.Biomedicines · 2023Review
- Precision medicine in inflammatory bowel disease: Individualizing the use of biologics and small molecule therapies.World journal of gastroenterology · 2023Review
- Precision medicine and drug optimization in adult inflammatory bowel disease patients.Therapeutic advances in gastroenterology · 2023Review
- Article
- Review
- Anti-Gut and liver · 2021Article
- Antibodies Against Glycoprotein 2 Are Specific Biomarkers for Pediatric Crohn's Disease.Digestive diseases and sciences · 2021Article
- Improving prediction of disease outcome for inflammatory bowel disease: progress through systems medicine.Expert review of clinical immunology · 2021Review
- Metagenetic Analysis for Microbial Characterization ofFoods (Basel, Switzerland) · 2021Article
- Fecal Bacteria Implicated in Biofilm Production Are Enriched and Associate to Gastrointestinal Symptoms in Patients With APECED - A Pilot Study.Frontiers in immunology · 2021Article
- Differential diagnosis of Crohn's disease using antibodies to glycoprotein 2 and Saccharomyces cerevisiae.The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology · 2019Article
- ASCA and ANCA among Bedouin Arabs with inflammatory bowel disease, the frequency and phenotype correlation.BMC gastroenterology · 2018Article
- Predicting outcomes to optimize disease management in inflammatory bowel disease in Japan: their differences and similarities to Western countries.Intestinal research · 2018Review
- Serologic testing of a panel of five antibodies in inflammatory bowel diseases: Diagnostic value and correlation with disease phenotype.Biomedical reports · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRecent studies suggested that anti-Saccharomyces cerevisiae antibody (ASCA) status was associated with diagnostic findings, stratified classification phenotypes, disease activity and clinical course of Crohn's disease (CD). However, the relationship between ASCA status and phenotypes of CD remains controversial in these studies.
aimsThe purpose of this study was to evaluate whether ASCA status is associated with the phenotypes and the risk of surgery in diverse populations in CD.
methodsWe conducted a meta-analysis of studies assessing the association of ASCA status with phenotypes and risk of surgery in CD. Three independent reviewers undertook data extraction. We pooled odds ratios separately for the cohort and case-control studies.
resultsWe identified ten cohort studies (n = 2,365) and 14 case-control studies (n = 1,887) that investigated the association of ASCA status with phenotypes and risk of surgery in CD. The meta-analysis of the cohort studies showed significant association between the ASCA-positive status and higher risk of early-onset age (OR 2.25, 95 % CI 1.41-3.57, P < 0.001), ileal involvement disease (1.70, 1.05-2.77, P = 0.03), complicated disease behavior (2.09, 1.71-2.57, P < 0.001), perianal disease (1.49, 1.14-1.94, P = 0.004), and risk for surgery (1.61, 1.29-2.01, P < 0.001). Meta-analysis of the case-control studies also showed a significantly higher risk in ileal involvement disease (1.77, 1.25-2.49, P = 0.001), complicated disease behavior (2.13, 1.70-2.68, P < 0.001), perianal disease (1.96, 1.38-2.78, P < 0.001), and risk for surgery (1.71, 1.17-2.49, P = 0.005), except for the early-onset age (1.16, 0.80-1.69, P = 0.44).
conclusionsThis meta-analysis indicated that positive ASCA status is a risk factor for early-onset age, ileal involvement, complicated behavior, perianal disease and requirement for surgery in CD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.